Cargando…

Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial

BACKGROUND: The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenners, Antonia, Grambach, Jana, Koss, Juliane, Maass, Nicolai, Jonat, Walter, Schmutzler, Andreas, Mundhenke, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588613/
https://www.ncbi.nlm.nih.gov/pubmed/28877720
http://dx.doi.org/10.1186/s12885-017-3593-x
_version_ 1783262208829947904
author Wenners, Antonia
Grambach, Jana
Koss, Juliane
Maass, Nicolai
Jonat, Walter
Schmutzler, Andreas
Mundhenke, Christoph
author_facet Wenners, Antonia
Grambach, Jana
Koss, Juliane
Maass, Nicolai
Jonat, Walter
Schmutzler, Andreas
Mundhenke, Christoph
author_sort Wenners, Antonia
collection PubMed
description BACKGROUND: The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy. METHODS: Fifty-one premenopausal women (28–46 years) with primary breast cancer were included in the trial. All of them received anthracycline-based chemotherapy (n = 18), or combinations with taxanes (n = 30), or anthracycline-free chemotherapy (n = 3). Changes in hormone levels (LH, FSH, E2 and Anti-Müllerian hormone (AMH)), antral follicle count (AFC), and amenorrhea were determined before (V1), and 6, 12 and 24 months after the initiation of chemotherapy (V2-V4). Quality of life parameters were evaluated. The additional impact of parity, BMI, and smoking on ovarian reserve was also assessed. RESULTS: AFC and AMH fell very markedly after chemotherapy and did not return to pre-treatment levels until V4. A significant positive correlation was noted in AFC before and 1 year after chemotherapy. AMH levels at V2-V4 were significantly correlated with those registered at V1. AFC and AMH were negatively correlated with age. Continued smoking had a significant detrimental effect on AFC after 24 months. LH and FSH levels increased between V1 and V2 and fell at V3 and V4, but stayed above pre-chemotherapy values. Two years after the start of chemotherapy 31/51 patients were amenorrhoic while 17 resumed their menstrual cycle; this was not influenced by the type of chemotherapy or age. Non-smokers were 13 times more likely to resume their menstruation than smokers. Quality of life (QL) was significantly lower 6 months after the initiation of chemotherapy. QL at one and 2 years after chemotherapy did not differ significantly from pre-chemotherapy scores. CONCLUSIONS: Our study contributes to a better understanding and prediction of ovarian reserve in young early breast cancer patients undergoing chemotherapy. The data suggest that personal counseling in regard of the preservation of fertility should be offered especially to patients of a higher age, with low AMH levels or low follicle counts. Patients should be advised to stop smoking in order to enhance the likelihood of preserving their fertility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3593-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5588613
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55886132017-09-14 Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial Wenners, Antonia Grambach, Jana Koss, Juliane Maass, Nicolai Jonat, Walter Schmutzler, Andreas Mundhenke, Christoph BMC Cancer Research Article BACKGROUND: The numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy. METHODS: Fifty-one premenopausal women (28–46 years) with primary breast cancer were included in the trial. All of them received anthracycline-based chemotherapy (n = 18), or combinations with taxanes (n = 30), or anthracycline-free chemotherapy (n = 3). Changes in hormone levels (LH, FSH, E2 and Anti-Müllerian hormone (AMH)), antral follicle count (AFC), and amenorrhea were determined before (V1), and 6, 12 and 24 months after the initiation of chemotherapy (V2-V4). Quality of life parameters were evaluated. The additional impact of parity, BMI, and smoking on ovarian reserve was also assessed. RESULTS: AFC and AMH fell very markedly after chemotherapy and did not return to pre-treatment levels until V4. A significant positive correlation was noted in AFC before and 1 year after chemotherapy. AMH levels at V2-V4 were significantly correlated with those registered at V1. AFC and AMH were negatively correlated with age. Continued smoking had a significant detrimental effect on AFC after 24 months. LH and FSH levels increased between V1 and V2 and fell at V3 and V4, but stayed above pre-chemotherapy values. Two years after the start of chemotherapy 31/51 patients were amenorrhoic while 17 resumed their menstrual cycle; this was not influenced by the type of chemotherapy or age. Non-smokers were 13 times more likely to resume their menstruation than smokers. Quality of life (QL) was significantly lower 6 months after the initiation of chemotherapy. QL at one and 2 years after chemotherapy did not differ significantly from pre-chemotherapy scores. CONCLUSIONS: Our study contributes to a better understanding and prediction of ovarian reserve in young early breast cancer patients undergoing chemotherapy. The data suggest that personal counseling in regard of the preservation of fertility should be offered especially to patients of a higher age, with low AMH levels or low follicle counts. Patients should be advised to stop smoking in order to enhance the likelihood of preserving their fertility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-017-3593-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-06 /pmc/articles/PMC5588613/ /pubmed/28877720 http://dx.doi.org/10.1186/s12885-017-3593-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wenners, Antonia
Grambach, Jana
Koss, Juliane
Maass, Nicolai
Jonat, Walter
Schmutzler, Andreas
Mundhenke, Christoph
Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title_full Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title_fullStr Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title_full_unstemmed Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title_short Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
title_sort reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588613/
https://www.ncbi.nlm.nih.gov/pubmed/28877720
http://dx.doi.org/10.1186/s12885-017-3593-x
work_keys_str_mv AT wennersantonia reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT grambachjana reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT kossjuliane reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT maassnicolai reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT jonatwalter reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT schmutzlerandreas reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial
AT mundhenkechristoph reducedovarianreserveinyoungearlybreastcancerpatientspreliminarydatafromaprospectivecohorttrial